Fennec Pharmaceuticals (FENC) financial statements
Fennec Pharmaceuticals reported revenue of $45M in fiscal 2025, up 204.7% a year over 5 years.
Net income was -$10M.
The diluted share count rose 124% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Fennec Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $170,000 | — | $2M | $21M | $48M | $45M |
| Cost of revenue | — | — | — | — | — | — | $86,000 | $1M | — | — |
| Gross profit | — | — | — | — | — | — | $1M | $20M | — | — |
| Research and development | $472,000 | $2M | $5M | $6M | $5M | $5M | $4M | $56,000 | $307,000 | $250,000 |
| Selling, general and admin | $2M | $5M | $5M | $7M | $13M | $12M | $21M | $33M | $41M | $47M |
| Operating income | -$3M | -$7M | -$10M | -$13M | -$18M | -$17M | -$23M | -$13M | $3M | -$6M |
| Interest expense | — | — | — | — | — | — | — | $3M | $4M | $2M |
| Pre-tax income | -$3M | -$7M | -$8M | -$9M | -$9M | -$9M | -$11M | -$16M | -$71,000 | -$10M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | $365,000 | $106,000 |
| Net income | -$3M | -$7M | -$10M | -$13M | -$18M | -$17M | -$24M | -$16M | -$436,000 | -$10M |
| EPS (diluted) | -$0.22 | -$0.47 | -$0.52 | -$0.64 | -$0.76 | -$0.67 | -$0.90 | -$0.60 | -$0.02 | -$0.34 |
| Diluted shares | 13M | 15M | 19M | 20M | 24M | 26M | 26M | 27M | 27M | 29M |
| Gross margin | — | — | — | — | — | — | 94.4% | 94.1% | — | — |
| Operating margin | — | — | — | — | -10520.6% | — | -1471.6% | -60.1% | 5.4% | -14.1% |
| Net margin | — | — | — | — | -10652.4% | — | -1544.9% | -75.5% | -0.9% | -21.8% |
Balance sheet
Fiscal years, from Fennec Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $4M | $28M | $23M | $14M | $30M | $21M | $24M | $13M | $27M | $37M |
| Total current assets | — | $28M | $23M | $14M | $31M | $22M | $27M | $27M | $44M | $67M |
| Total assets | $4M | $28M | $23M | $14M | $31M | $22M | $27M | $27M | $45M | $71M |
| Total current liabilities | $402,000 | $2M | $2M | $2M | $2M | $2M | $5M | $8M | $7M | $11M |
| Long-term debt | — | — | — | — | — | $5M | — | — | — | — |
| Total liabilities | $402,000 | $2M | $2M | $2M | $2M | $7M | $30M | $38M | $51M | $35M |
| Shareholders' equity | $4M | $27M | $21M | $12M | $29M | $16M | -$3M | -$12M | -$6M | $35M |
| Net debt | -$4M | -$28M | -$23M | -$14M | -$30M | -$16M | -$24M | -$13M | -$27M | -$37M |
Cash flow
Fiscal years, from Fennec Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2M | -$4M | -$8M | -$9M | -$16M | -$14M | -$18M | -$17M | $27M | -$12M |
| Stock-based compensation | $615,000 | $2M | $2M | $3M | $3M | $4M | $4M | $5M | $5M | $7M |
| Net borrowing | — | — | — | — | — | $5M | $20M | $5M | -$13M | -$19M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for FENC.
Open FENC in InvestinglyQuestions
What was Fennec Pharmaceuticals's revenue in 2025?
$45M in fiscal 2025, from its 10-K filing.
From Fennec Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.